Full Press Release Details
Grant of share options
15, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company
developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the grant of the following share
options to directors and members of senior management:
| Matthew Davis | Chief Medical Officer and acting Chief Scientific Officer | 375,000 Options | ||||
| Keeren Shah | Chief Financial Officer | 187,500 Options | ||||
| Jules Jacob | Executive Director of Chemistry, Manufacturing, Controls & Non-Clinical Development | 85,000 Options | ||||
| Vaseem Palejwala | Senior Director, Clinical Operations | 60,000 Options | ||||
| John Brancaccio | Non-executive director | 75,000 Options | ||||
| Willy Simon | Non-executive director | 75,000 Options |
for all options is $0.57 per share. The options all vest in 4 equal tranches over 4 years, with the first tranche vesting on 15 March
2024, and all options have a life of ten years from date of grant.
Activated T cells play an important role
in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens
inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated
in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected
to start in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of
inflammatory human diseases.1
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab,
the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's
technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad
pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor
+44 (0) 207 495 2379
LifeSci Advisors, LLC